ZETA-1 Phase 2 Trial Safety and Tolerability Results for APX3330: A Novel, Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy
APX3330
Presented at Women in Ophthalmology 2023
Filter by:
Presented at Women in Ophthalmology 2023
Presented at American Society of Retina Specialists 2023
Presented at American Society of Retina Specialists 2023
Presented at American Society of Cataract and Refractive Surgery 2023
Presented at Association for Research in Vision and Ophthalmology 2023
Presented at Association for Research in Vision and Ophthalmology 2023
Presented at the Macula Society 46th Annual Meeting
Bascom Palmer Eye Institute
Presented at American Academy of Ophthalmology 2021